A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 (BTL-TML-COVID)

Beech Tree Labs

Status and phase: Completed; Phase 2

Conditions: SARS-CoV-2 Infection

Treatments: Drug: BTL-TML-COVID; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04522830

2020-04-0311

Details and patient eligibility

About

Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.

Enrollment: 28 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 40 years of age or older
• Provide written informed consent
• Have a SARS-COV-19 diagnostic test with positive results

Exclusion criteria

• Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
• Subjects currently hospitalized
• Subjects who have received a COVID vaccination
• Subjects with a diagnosis of immunodeficiency

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

28 participants in 2 patient groups, including a placebo group

BTL-TML-COVID

Experimental group

Description:

BTL-TML-COVID

Treatment:

Drug: BTL-TML-COVID

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo